Is It Worth Investing in Lantheus Stock from the Philippines in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Lantheus for over three years. Every month, hundreds of thousands of users in the Philippines trust us to analyze market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Lantheus.

What is Lantheus?

What is the price of Lantheus stock?

The price of Lantheus stock is slightly down this week. Lantheus is currently trading at $83.49 after a 1.31% rise in the past 24 hours, though the weekly change shows a 4.86% decline. The company’s market capitalization stands at $5.78 billion, with a 3-month average volume of 1.13 million shares. Its P/E ratio is 23.66, it pays no dividend, and the beta is a low 0.12, indicating very limited price volatility. Given its stable fundamentals and recent strategic acquisitions, Lantheus appeals to PH investors seeking steady growth in healthcare.

Our Full Analysis of Lantheus Stock

Following a comprehensive review of Lantheus’s latest financial results and its stock performance over the past three years, we have leveraged our proprietary algorithms to synthesize a blend of leading financial indicators, technical signals, market data, and peer analysis. This approach yields a high-confidence perspective on where Lantheus stands relative to its competitors and its outlook going forward. So, why might Lantheus stock once again become a strategic entry point into the radiopharmaceuticals sector in 2025?

Recent performance and market context

Lantheus shares are currently trading at $83.49, having registered a daily advance of +1.31%. While the past week saw a modest pullback of 4.86%, this adjustment contrasts a resilient +7.45% advance over the last twelve months, outperforming many specialized healthcare peers. The last year also showcased robust price resilience after a broader correction—reflecting how the market has efficiently absorbed sector volatility.

The latest operational milestones reinforce confidence: key acquisitions of Evergreen Theragnostics and Life Molecular Imaging in 2025 are already broadening the company's clinical development reach and solidifying its leading position in imaging and diagnostics for oncology and cardiology. Furthermore, the industry-wide expansion in demand for high-precision diagnostics remains sustained by favorable macroeconomic winds, particularly as global health systems continue to invest in innovative diagnostic technologies. The healthcare and biotech sectors, seen as defensive in the current market context, add another layer of appeal for investors in the Philippines looking for resilient international exposure.

Technical analysis

The technical setup for Lantheus is overwhelmingly constructive, pointing to a potential bullish pivot. The RSI at 62.8, well within a buy zone and comfortably below overbought levels, confirms ongoing accumulation. MACD readings are positive (0.75) and trending upward, reinforcing momentum. What stands out is the powerful alignment of all relevant moving averages—MA 20 ($81.71), MA 50 ($80.95), MA 100 ($80.41), and MA 200 ($79.61)—all signaling “buy” and acting as robust support.

Current trading shows solid support at $80.59 (key 100-day EMA), while short-term resistance is observed at $85.20—a modest threshold should the bullish trend continue. A technical “strong buy” consensus, backed by 12 buy versus 0 sell signals for moving average indicators, provides tactical reassurance that Lantheus may be entering a renewed upward momentum phase. For investors seeking a technically sound entry, the current setup offers an attractive risk/reward ratio.

Fundamental analysis

Revenue growth remains the structural pillar for Lantheus. Q1 2025 delivered sales of $372.8 million, up 0.8% year-over-year—even as short-term profit margins were impacted by nonrecurring items and integration costs from strategic acquisitions. The annual revenue guidance for 2025 ($1.55–$1.585 billion) reflects both organic expansion and incremental contributions from acquired platforms.

From a profitability lens, while Q1 net income was temporarily softer ($72.9 million), the long-term P/E at 23.66 and a forward P/E of just 12.40 demonstrate a compelling valuation for a growth stock operating in a specialized healthcare niche. With a dominant market position in radiopharmaceuticals, patented products such as PYLARIFY (poised for >$1 billion in annual sales) and DEFINITY support recurring, high-margin revenue streams that are resilient to competitive shocks. Regulatory and technical barriers to entry provide long-term sustainability, while sector leadership in innovation and market share underpin Lantheus’s “moat.”

Competitive differentiation extends beyond simple product leadership: Lantheus’s cutting-edge work in AI-assisted imaging, a robust post-acquisition R&D pipeline, and growing partnerships with hospital networks serve as powerful levers for future growth. The company’s balance sheet remains healthy, with robust free cash flow supporting both M&A ambitions and ongoing reinvestment in innovation.

Volume and liquidity

Consistent trading volume averaging 1.13 million shares over three months reflects healthy and stable buy-side demand, an essential factor for investor confidence and liquidity-minded institutional flows. The public float remains highly favorable, supporting efficient price discovery and the ability for new entrants to establish meaningful positions without experiencing illiquidity or undue volatility. For PH investors accustomed to vibrant domestic equities, Lantheus offers a seamless, liquid gateway to the US healthcare innovation ecosystem.

Catalysts and positive outlook

• Product milestones: PYLARIFY’s trajectory toward $1B+ annual revenue cements its status as a blockbuster diagnostic product.
• Strategic acquisitions: The 2025 integrations of Evergreen Theragnostics and Life Molecular Imaging not only expand manufacturing and clinical reach, but also reinforce entry into high-growth Alzheimer’s diagnostics.
• Divestitures: The sale of SPECT activity to SHINE Technologies enables a sharper focus on innovation in radiopharmaceuticals, optimizing growth potential.
• R&D and innovation: A rejuvenated development pipeline—backed by increased investment post-acquisition—amplifies Lantheus’s first-mover advantage as precision diagnostics become standardized in oncology care.
• ESG and regulatory tailwinds: Growing awareness of early cancer detection and regulatory preference for advanced diagnostic imaging worldwide bolsters Lantheus’s market potential.
• Sector sentiment: The healthcare and biotech sectors remain favored as international investors seek resilient and defensive growth amid fluctuating macroeconomic signals.

A notable near-term catalyst is the upcoming Q2 2025 results, scheduled for July 30. Any signal of an uptick in adoption rates or upside surprise in quarterly sales could validate current bullish forecasts, leading to positive revisions in consensus price targets.

Investment strategies

• Short-term traders: May identify favorable volatility near technical lows ($80–$85), with the potential for quick rebounds, particularly ahead of earnings or product news. A clear breakout above $85.20 offers momentum-driven traders a precise tactical entry.
• Medium-term investors: Benefit from holding into the ongoing integration of recent acquisitions, betting on progressive upward re-rating as synergies are realized, pipeline news is released, and new revenue streams come online.
• Long-term investors: Stand to gain from the intrinsic growth of the radiopharmaceuticals segment, increasing demand for precision diagnostics, and Lantheus’s embedded sector leadership. Attractive valuation multiples and sectoral “moat” characteristics may underpin multi-year compound returns.

For PH-based investors seeking diversification outside the local market, Lantheus stock provides both a play on global healthcare innovation and an uncorrelated asset relative to most regional index components.

Is it the right time to buy Lantheus?

• Strong technical momentum and healthy price support,
• Attractive valuation for a market leader with accelerating top-line growth,
• Robust trading liquidity confirming underlying investor confidence,
• Convincing competitive strengths based on product innovation, market share, and successful M&A,
• Clear, actionable catalysts in the near and medium term,
• Defensive characteristics suited to uncertain or inflationary environments.

While all equity investments involve risk and prudent portfolio construction is essential, the case for renewed interest in Lantheus at current levels seems notably justified. The convergence of technical signals, sustained business performance, and a packed catalyst pipeline suggests the stock may be entering a new bullish phase. For well-prepared PH investors eager to capitalize on high-potential healthcare innovation, Lantheus seems to represent an excellent opportunity to position now—at the heart of a sector primed for growth and transformation. The next few months could well mark a strategic inflection for those attentive to this emerging leader.

How to buy Lantheus stock in the Philippines?

Buying Lantheus stock online is both simple and secure when you use a regulated broker. Investors in the Philippines can choose between two main methods: spot (cash) buying, providing direct share ownership, or trading via CFDs (Contracts for Difference) for flexible, leveraged exposure. Whether you prefer long-term investing or short-term trading, online brokers make the process fast and accessible. For those ready to start, a full broker comparison is available further down the page to help you make an informed choice.

Spot buying

A cash purchase of Lantheus stock means you own the shares directly, entitling you to potential price gains over time. Brokers typically charge a fixed commission per order—around PHP 250–500 (about $5–$10).

Gain scenario

If the Lantheus share price is $83.49, you can buy around 11 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading on Lantheus shares means speculating on the share price movement without owning the actual stock. Fees generally include the spread (the broker’s buy/sell price difference) and possible overnight financing if the position is held for more than a day. CFDs let you use leverage for greater exposure to price changes, but carry higher risk.

Gain Scenario on a CFD Position

You open a CFD position on Lantheus shares, with 5x leverage.

This gives you a market exposure of $5,000.

✔️ Gain scenario:

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Always compare brokers’ fees, trading platforms, and support for investors in the Philippines before placing your first order. Whether you choose spot buying or CFDs depends on your personal goals—long-term value building, or short-term active trading. Our broker comparison further down the page will help you start your investment journey confidently.

Our 7 tips for buying Lantheus stock

The latest news about Lantheus

Lantheus completed two major acquisitions in 2025, expanding diagnostics and Alzheimer’s imaging capabilities. In January and April, Lantheus acquired Life Molecular Imaging and Evergreen Theragnostics, strengthening its portfolio in Alzheimer's diagnostics and radiopharmaceutical development. This enhances its strategic reach, including potential distribution in new global markets with growing healthcare needs.

Lantheus reported strong technical buy signals, with all key moving averages supporting a positive trend. As of July 2025, the stock trades above its 20, 50, 100, and 200-day moving averages, backed by a “Strong Buy” technical consensus. The RSI and MACD both indicate continued upward momentum, reinforcing a favorable outlook for near-term performance.

PYLARIFY and DEFINITY, Lantheus’s flagship products, continue to drive revenue growth and market dominance. PYLARIFY delivered $257.7 million in Q1 2025 revenues, set to surpass $1 billion in annual sales, while DEFINITY maintained solid top-line growth. These products drive leadership in precision imaging, a sector gaining traction across Asia-Pacific healthcare systems.

Lantheus forecasted 2025 revenue to reach up to $1.585 billion, reflecting continued sector expansion. Company guidance anticipates a 1–4% annual revenue increase, demonstrating robust demand for advanced diagnostics. The expanding radiopharmaceuticals market and new product launches offer multiple long-term opportunities for global growth.

Recent divestiture of SPECT business sharpens Lantheus’s strategic focus on innovative radiopharmaceuticals. By selling its SPECT division to SHINE Technologies in May 2025, Lantheus is reallocating resources to growth segments like oncology and neurology diagnostics, positioning itself for higher value creation in the context of changing healthcare priorities, including in the Philippines.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.